Half dose DOAC maintenance noninferior to full DOAC. Potential practice changing paper to reduce the risk of bleeding in patients who are rec. to receive >6mo anticoagulation. Take typical caution in industry funded research with a non-inferiority design, and low incidence of primary outcome.
Reposted from
NEJM.org
In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full results: nej.md/41YkRZK
#ACC25 | @accintouch.bsky.social
#ACC25 | @accintouch.bsky.social
Comments